Daniel Lebovic, MD
Hematology & Oncology · Grosse Pointe Woods, MINPI 1740302850
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $328,825 of the $351,663 with a category attached, or 93.5%. 28 manufacturers reported payments, led by Sanofi at 27.8% of the total. Reporting peaked in 2019 at $98,314 and has fallen 78.2% since, to $21,431 in 2025. Among hematology & oncology clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 280 payments — averaging $1255.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$98K
- Amgen$91K
- Bristol Myers Squibb$53K
- Takeda Pharmaceuticals U.S.A., Inc.$41K
- AbbVie$32K
- Genentech USA, Inc.$20K
- plus $17K from 22 others
Across 133 payments — averaging $2483.66 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Seagen Inc.$175K
- Eli Lilly$88K
- Genentech, Inc.$21K
- Redhill Biopharma Inc.$18K
- Pharmacyclics LLC, An Abbvie Company$17K
- Beone Medicines USA, Inc.$9K
- plus $1K from 1 others
What the payments were for
- Consulting fees$12,5194%
- Speaking & faculty fees$328,82594%
- Travel & lodging$6,9822%
- Food & beverage$3,2241%
- Education$1130%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 52 | $97,808 |
| Amgen | 56 | $91,321 |
| Bristol Myers Squibb | 37 | $52,847 |
| Takeda Pharmaceuticals U.S.A., Inc. | 26 | $40,619 |
| AbbVie | 19 | $31,559 |
| Genentech USA, Inc. | 15 | $20,485 |
| Pharmaessentia USA Corporation | 5 | $8,785 |
| Epizyme, Inc. | 6 | $6,250 |
| TG Therapeutics, Inc. | 2 | $563 |
| GSK | 13 | $253 |
| Johnson & Johnson | 9 | $229 |
| AstraZeneca(2 entities) | 8 | $212 |
| Adaptive Biotechnologies Corporation | 2 | $137 |
| Janssen Scientific Affairs, LLC | 1 | $97 |
| E.r. Squibb & Sons, L.L.C. | 5 | $93 |
| Novartis | 5 | $73 |
| Merck | 2 | $48 |
| Eisai Inc. | 2 | $46 |
| Pfizer | 3 | $45 |
| Jazz Pharmaceuticals Inc. | 2 | $33 |
| Exelixis Inc. | 2 | $29 |
| Kyowa Kirin, Inc. | 2 | $26 |
| Gilead | 1 | $23 |
| Sobi, Inc | 1 | $21 |
| Genmab U.S., Inc. | 1 | $19 |
| Servier Pharmaceuticals LLC | 1 | $16 |
| Astellas Pharma US Inc | 1 | $14 |
| Incyte Corporation | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$351,663 in reported general payments places this provider in the 95th percentile of 282 hematology & oncology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 97 | $1,620,304 |
| Lenalidomide | 77 | $979,852 |
| ImbruvicaIbrutinib | 64 | $934,359 |
| VenclextaVenetoclax | 54 | $617,574 |
| PomalystPomalidomide | 25 | $574,719 |
| BrukinsaZanubrutinib | 45 | $510,599 |
| BosulifBosutinib | 25 | $504,150 |
| JakafiRuxolitinib Phosphate | 26 | $330,214 |
| OjjaaraMomelotinib Dihydrochloride | 12 | $323,642 |
| Sandostatin Lar DepotOctreotide Acetate,mi-Spheres | 52 | $308,918 |
| SprycelDasatinib | 23 | $303,243 |
| VonjoPacritinib Citrate | 12 | $170,158 |
| EliquisApixaban | 152 | $125,295 |
| BesremiRopeginterferon Alfa-2b-Njft | 13 | $118,144 |
| XareltoRivaroxaban | 34 | $37,304 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $52,847 | $1,620,30497 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst, Sprycel | $93 | $877,96348 claims |
| PfizerBosulif, Eliquis | $45 | $629,445177 claims |
| AbbVieVenclexta | $31,559 | $617,57454 claims |
| Incyte CorporationJakafi | $12 | $330,21426 claims |
| GSKOjjaara | $253 | $323,64212 claims |
| NovartisSandostatin Lar Depot | $73 | $308,91852 claims |
| Pharmaessentia USA CorporationBesremi | $8,785 | $118,14413 claims |
| Johnson & JohnsonXarelto | $229 | $37,30434 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 282 hematology & oncology providers in Michigan.
Other hematology & oncology in Grosse Pointe Woods
- Faisal MusaDearborn$976K
- Mohammed Al HallakDetroit$644K
- Sreenivasa ChandanaGrand Rapids$305K
- Mohammad ChistiTroy$180K
- Gordon SrkalovicLansing$167K
- Jeffrey ZonderDetroit$88K
- Madan AroraFlint$84K
- Hadeel AssadDetroit$80K
- Andrew MuskovitzSouthfield$45K
- Wasif SaifDetroit$44K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.